Ivosidenib confers clinical benefit in advanced cholangiocarcinoma subset

Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated advanced cholangiocarcinoma, according to final results of the phase 3 ClarIDHy trial presented at Gastrointestinal Cancers Symposium.The agent also appeared well-tolerated compared with placebo.“Cholangiocarcinoma is a rare, aggressive malignancy with limited effective treatment options,” Andrew X. Zhu, MD, PhD, director of liver cancer research at Massachusetts General Hospital and professor of medicine at Harvard Medical School, said during his presentation. “IsocitrateRead More

Share on facebook
Share on twitter
Share on linkedin